| Filed On | Filing |
|---|---|
| 16 Oct 2026 |
8-K/A: Financial Statements and Exhibits
On August 5, 2026, Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) acquired Cy Biopharma, Inc. (“Cy”), pursuant to the terms of an Agreement and Plan of Merger, dated August 5, 2026 (the “Merger Agreement”), by and among Ensysce, ... |
| 06 Aug 2026 |
8-K/A: Financial Statements and Exhibits
Acquisition includes clinical-stage neuroplastogenic therapy with U.S. FDA Orphan Drug Designation for the treatment of Complex Regional Pain Syndrome (CRPS) |
| 30 Jun 2021 | 8-K/A: Submission of Matters to a Vote of Security Holders |
Loading...
